|
Sep 9
|
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
|
|
Sep 9
|
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
|
|
Jun 24
|
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 2
|
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 5
|
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
|
|
Apr 5
|
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
|
|
Apr 5
|
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
|
|
Mar 13
|
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Nov 30
|
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
|
|
Sep 10
|
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
|
|
Sep 5
|
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
May 2
|
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
|
|
Apr 28
|
Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
|